Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2006-11-29

FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental NDA to add an intramuscular formulation of ZYPREXA (olanzapine) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYPREXA INTRAMUSCULAR (olanzapine)

Snippet

SUPPL AP for ZYPREXA INTRAMUSCULAR (OLANZAPINE)